Abstract: The invention relates to substituted 4-,6- or 7-hydroxyindoles with N-oxide groups, process for their preparation, pharmaceutical preparations which comprise these compounds, and the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active ingredients for the treatment of disorders which can be influenced by inhibition of phosphodiesterase 4 activity in particular in immunocompetent cells (e.g. macrophages and lymphocytes) by the compounds of the invention.

Abstract: The invention relates to substituted 7-azaindoles, process for their preparation, pharmaceutical preparations which comprise these compounds, and the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active ingredients for the treatment of disorders which can be influenced by inhibition of phosphodiesterase 4 activity in particular in immunocompetent cells (e.g. macrophages and lymphocytes) by the compounds of the invention.

Abstract: The invention relates to substituted 4- or/and 7-hydroxyindoles, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active compounds for treating diseases which can be influenced by using the compounds according to the invention to inhibit phosphodiesterase 4 activity in immunocompetent cells (e.g. macrophages and lymphocytes).

Abstract: The invention relates to the use of hydroxyindolylglyoxylamides as inhibitors of phosphodiesterase 4 for the treatment of nonallergic rhinitis.

Abstract: The present invention relates to a method for the treatment of an inflammatory and/or allergic skin disease comprising topically administering a substituted hydroxy indol.

Abstract: The invention relates to 2,5-dihydropyrazolo[3,4-d]pyrimidin-4-ones and their tautomers which contain in the 5-position an ar(alkyl) radical and in the 2-position a hydrogen or an ar(alkyl) radical, processes for their preparation and their use as medicaments, in particular for the treatment of epilepsy of various forms.

Abstract: The invention relates to 1,5-dihydropyrrol-2-ones of Formula 1 which contain an aryl radical in the 1-position and a secondary amine radical in the 4-position, to a process for making and for a process to treat various forms of epilepsies and of states of anxiety and tension.

Abstract: A selective modulatory retigabine binding potassium channel receptor site containing subunits KCNQ2 and KCNQ3, and a method for directly selectively modulating that receptor site by administering retigabine to a cell preparation of the potassium channel.

Abstract: The invention relates to the use of 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonylaminobenzene of formula I ##STR1## or its pharmaceutically utilizable salts, for the prophylaxis and treatment of neuropathic pain.

Abstract: A process for the treatment of anxiety and tension, which comprises administering to a patient in need therefor an anxiolytically effective amount of a compound of the formula ##STR1## wherein X is hydrogen, a C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trifluoromethyl residue, or halogen; R.sup.1 and R.sup.2 are independently of each other a C.sub.1-4 alkyl, cycloalkyl, C.sub.2-4 hydroxyalkyl, or heteroalkyl residue, or R.sup.1 and R.sup.2 together form a C.sub.2-6 alkylene residue in which one --CH.sub.2 -- group can be replaced by oxygen, nitrogen or sulfur; n is 0 or 1, and m is 0 or a cardinal number from 1-5, or a pharmaceutically acceptable salt of the compound.

Abstract: The use of the compound I ##STR1## or its pharmaceutically utilizable salts for the propylaxis and treatment of the squelae of chronic reduced cerebral blood supply, in particular of stroke, and for the treatment of nuerodegenerative disorders is claimed.

Abstract: The use of the compound I ##STR1## or its pharmaceutically utilizable salts for the propylaxis and treatment of the sequel of chronic reduced cerebral blood supply, in particular of stroke, and for the treatment of neurodegenerative disorders is claimed.